Insider Selling: Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Sells 5,850 Shares of Stock

Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Marc N. Casper sold 5,850 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $557.89, for a total transaction of $3,263,656.50. Following the sale, the chief executive officer now owns 121,192 shares of the company’s stock, valued at approximately $67,611,804.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Thermo Fisher Scientific Stock Down 0.4 %

Shares of NYSE:TMO traded down $2.45 during trading on Monday, hitting $555.47. The company’s stock had a trading volume of 815,100 shares, compared to its average volume of 1,463,423. The company has a market capitalization of $212.19 billion, a PE ratio of 34.98, a PEG ratio of 3.61 and a beta of 0.79. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. Thermo Fisher Scientific Inc. has a fifty-two week low of $437.26 and a fifty-two week high of $627.88. The stock’s 50-day moving average price is $599.39 and its two-hundred day moving average price is $583.76.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. The business had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company’s quarterly revenue was up .2% on a year-over-year basis. During the same period in the previous year, the business posted $5.69 EPS. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current year.

Hedge Funds Weigh In On Thermo Fisher Scientific

A number of hedge funds and other institutional investors have recently modified their holdings of TMO. Chartwell Investment Partners LLC raised its position in Thermo Fisher Scientific by 45.8% during the third quarter. Chartwell Investment Partners LLC now owns 17,496 shares of the medical research company’s stock valued at $10,823,000 after acquiring an additional 5,496 shares in the last quarter. Peregrine Asset Advisers Inc. increased its stake in Thermo Fisher Scientific by 830.5% in the third quarter. Peregrine Asset Advisers Inc. now owns 5,313 shares of the medical research company’s stock valued at $3,286,000 after acquiring an additional 4,742 shares during the period. Kennebec Savings Bank acquired a new position in shares of Thermo Fisher Scientific in the 3rd quarter worth approximately $761,000. Ashton Thomas Securities LLC boosted its position in Thermo Fisher Scientific by 90.3% in the third quarter. Ashton Thomas Securities LLC now owns 1,817 shares of the medical research company’s stock valued at $1,124,000 after buying an additional 862 shares in the last quarter. Finally, Los Angeles Capital Management LLC grew its holdings in shares of Thermo Fisher Scientific by 114.5% during the third quarter. Los Angeles Capital Management LLC now owns 12,102 shares of the medical research company’s stock worth $7,486,000 after purchasing an additional 6,459 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analysts Set New Price Targets

TMO has been the topic of a number of recent analyst reports. TD Cowen lifted their price objective on Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Robert W. Baird lowered their target price on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Stifel Nicolaus dropped their price target on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. Sanford C. Bernstein reduced their price target on Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating for the company in a research report on Thursday, October 24th. Finally, UBS Group raised Thermo Fisher Scientific to a “strong-buy” rating in a report on Monday, September 16th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $649.33.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.